The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
8-((8-fluoro-2H-benzo[b][1,4]oxazin-4(3H)-yl)methyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide ID: ALA3799831
PubChem CID: 127046317
Max Phase: Preclinical
Molecular Formula: C25H26FN3O5
Molecular Weight: 467.50
Molecule Type: Small molecule
Associated Items:
Names and Identifiers Canonical SMILES: CN(C)C(=O)c1cc(CN2CCOc3c(F)cccc32)c2oc(N3CCOCC3)cc(=O)c2c1
Standard InChI: InChI=1S/C25H26FN3O5/c1-27(2)25(31)16-12-17(15-29-8-11-33-24-19(26)4-3-5-20(24)29)23-18(13-16)21(30)14-22(34-23)28-6-9-32-10-7-28/h3-5,12-14H,6-11,15H2,1-2H3
Standard InChI Key: ZCBWPTBPKMKOLE-UHFFFAOYSA-N
Molfile:
RDKit 2D
34 38 0 0 0 0 0 0 0 0999 V2000
-2.6111 0.7486 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.6111 -0.7486 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.2964 -1.4973 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.2964 1.4973 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.0000 0.7486 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.0000 -0.7486 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.2964 -1.4973 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
2.5929 -0.7486 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.5929 0.7486 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.2964 1.4973 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.2964 2.6973 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
3.8926 -1.4990 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
5.1929 -0.7510 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.4908 -1.5029 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.4885 -3.0029 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
5.1883 -3.7510 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.8904 -2.9990 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.9091 1.5019 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.9494 0.9039 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-3.9067 3.0027 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-1.2907 -2.9981 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.2854 -5.9968 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.2727 -7.5097 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.5676 -8.2615 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.8751 -7.5005 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.9447 3.6050 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.8664 3.6008 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.5838 -5.2516 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.8786 -6.0034 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-5.1770 -5.2582 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-5.1805 -3.7611 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.8857 -3.0093 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.5870 -3.7544 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-4.9147 -8.0999 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 6 2 0
5 4 2 0
4 1 1 0
5 6 1 0
5 10 1 0
6 7 1 0
7 8 1 0
8 9 2 0
9 10 1 0
10 11 2 0
12 13 1 0
12 17 1 0
13 14 1 0
14 15 1 0
15 16 1 0
16 17 1 0
8 12 1 0
1 18 1 0
18 19 2 0
18 20 1 0
3 21 1 0
21 33 1 0
28 22 2 0
22 23 1 0
23 24 2 0
24 25 1 0
25 29 2 0
20 26 1 0
20 27 1 0
28 29 1 0
28 33 1 0
29 30 1 0
30 31 1 0
31 32 1 0
32 33 1 0
25 34 1 0
M END Associated Targets(Human) Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 467.50Molecular Weight (Monoisotopic): 467.1856AlogP: 2.87#Rotatable Bonds: 4Polar Surface Area: 75.46Molecular Species: NEUTRALHBA: 7HBD: ┄#RO5 Violations: ┄HBA (Lipinski): 8HBD (Lipinski): ┄#RO5 Violations (Lipinski): ┄CX Acidic pKa: ┄CX Basic pKa: ┄CX LogP: 2.71CX LogD: 2.71Aromatic Rings: 3Heavy Atoms: 34QED Weighted: 0.58Np Likeness Score: -0.97
References 1. Barlaam B, Cosulich S, Degorce S, Fitzek M, Green S, Hancox U, Lambert-van der Brempt C, Lohmann JJ, Maudet M, Morgentin R, Péru A, Plé P, Saleh T, Ward L, Warin N.. (2016) Discovery of a series of 8-(2,3-dihydro-1,4-benzoxazin-4-ylmethyl)-2-morpholino-4-oxo-chromene-6-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours., 26 (9): [PMID:26996374 ] [10.1016/j.bmcl.2016.03.034 ]